-
12.05.2019 | CARB-X funds Vedanta Biosciences to accelerate the development of a new category of oral therapeutics to help a patient’s microbiota fight drug-resistant bacteria
CARB-X is awarding Vedanta Biosciences, of Cambridge, MA, USA, up to $5.8 million in non-dilutive funding, with the possibility of $3.5 million more if certain project milestones are met, to develop a new category of oral therapeutics designed to restore a patient’s healthy microbiota so that it can fight multi-drug-resistant bacteria.
-
11.25.2019 | CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea
CARB-X is awarding VenatoRx Pharmaceuticals, Inc. (Malvern, Pennsylvania, USA) up to US $4.1 million in non-dilutive funding, with the possibility of up to an additional US $8.9 million if certain project milestones are met, to develop a new class of oral antibiotics to treat multi-drug-resistant (MDR) gonorrhea.
-
11.20.2019 | T2 Biosystems Announces Granting of CE-Mark for T2Resistance™ Panel
The T2Resistance Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections
-
11.06.2019 | CARB-X funds Techulon to support the development of innovative nano therapeutics capable of killing drug-resistant bacteria by precisely targeting essential genes
Techulon project is the 50th project funded by CARB-X since it was launched in 2016
-
10.29.2019 | CARB-X funds BioVersys to support the development of first-in-class anti-virulence small molecule drugs designed to disarm bacteria, opening the door for a paradigm shift in the treatment of drug resistant bacterial infections
BioVersys’ new medicine would be used as a stand-alone to treat uncomplicated skin and skin structure infections (SSSI) or in combination with antibiotics for more severe infections
-
09.24.2019 | T2 Biosystems’ T2Resistance™ Panel is First Diagnostic to Graduate from CARB-X Portfolio
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, and CARB-X, a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria, announced today that the T2Resistance™ Panel is the first diagnostic to graduate from CARB-X’s portfolio. The graduation marks an important milestone on the path toward approval for use on patients in hospitals in the U.S., Europe and elsewhere around the globe.
-
09.17.2019 | CARB-X funds Procarta Biosystems to develop oligonucleotide-based antibiotics to combat life-threatening Gram-negative pathogens
CARB-X is awarding Procarta Biosystems, a UK-based biotech company, up to US$2.2 million in non-dilutive funding with the possibility of $7.0 million more if certain project milestones are met, to develop a new class of antibiotics to treat Gram-negative ESKAPE pathogens. The new antibiotics are based on Procarta’s oligonucleotide antimicrobial platform. While still in preclinical development, if eventually approved for use in patients, Procarta’s PRO-202 antibiotics could be used to treat serious infections associated with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).
-
09.11.2019 | 2018-19 Annual Report: Progress in CARB-X’s fight against drug-resistant bacteria with new funding, expertise and strategic focus
CARB-X’s 2018-19 Annual Report has just been published, detailing a year of solid progress in its funding and support of antibacterial R&D to address the rise of drug-resistant bacteria. In its third year of operation, CARB-X further expanded its partnership, increased funding for R&D, expanded the scientific diversity of its portfolio, and established a global network of accelerators to provide expertise and support to funded product developers around the world.
-
09.03.2019 | CARB-X Strengthens Leadership Team with Appointment of Erin Duffy as Chief of Research and Development (R&D)
CARB-X, a global partnership led by Boston University, today announced the appointment of Erin Duffy, PhD, as Chief of Research and Development (R&D). Dr. Duffy will be responsible for the delivery of CARB-X’s global portfolio objectives through her leadership of the R&D alliance teams and the management and governance of CARB-X’s portfolio and funding cycles. Dr. Duffy will join CARB-X’s senior executive team and also sit on CARB-X’s governing body, the Joint Oversight Committee (JOC).
-
09.03.2019 | CARB-X funds SutroVax to develop a new vaccine to prevent Group A Streptococcal infections
CARB-X, a global partnership led by Boston University, is awarding SutroVax of Foster City, California, USA, up to $1.64 million in non-dilutive funding with the possibility of $13.4 million more if certain project milestones are met, to develop an innovative vaccine to prevent Group A Streptococcus (GAS) infections in developing countries and in the developed world.
-
08.20.2019 | CARB-X funds Vaxxilon AG to develop a new vaccine to prevent carbapenem-resistant superbug Klebsiella pneumoniae infections
CARB-X, a global partnership led by Boston University, is awarding Vaxxilon AG of Reinach, Switzerland, up to $1.4 million in non-dilutive funding with the possibility of $3.1 million more if certain project milestones are met, to develop a multivalent vaccine to prevent infections caused by carbapenem-resistant bacteria Klebsiella pneumoniae, an invasive Gram-negative superbug associated with life-threatening intensive-care and hospital-acquired infections and high mortality rates.
-
08.15.2019 | CARB-X funds Integrated Biotherapeutics to expand the development of its Staphylococcus aureus vaccine to facilitate use in the developing world
CARB-X, a global partnership led by Boston University, is awarding Integrated Biotherapeutics (IBT) of Rockville, Maryland, USA, $1.6 million to expand the development of its vaccine against Staphylococcus aureus, including Methicillin-resistant Staphylococcus aureus (MRSA) superbugs, so that the vaccine can be used to prevent infections in developing nations, as well as in the developed world. Under this initiative, IBT will expand its R&D to evaluate the efficacy of its vaccine, IBT-V02, against strains of the bacteria found in developing nations, and will also explore development of a freeze-dried version of the vaccine so that it can be used where cold storage systems are not available.
-
07.31.2019 | CARB-X funds BB100 to develop a unique monoclonal antibody to prevent and treat hyper-virulent multi-drug-resistant E. coli infections
CARB-X, a global partnership led by Boston University, is awarding BB100 LLC, a subsidiary of Bravos Biosciences of Schenectady, New York, USA, up to $3.0 million in non-dilutive funding with the possibility of $6.2 million more if certain project milestones are met, to develop a novel monoclonal antibody to prevent or treat serious life-threatening infections caused by a particularly virulent strain of Gram-negative multi-drug-resistant Escherichia coli (E. coli) called ST131-025b, which is often associated with complicated urinary tract, bloodstream, and prostate infections.
-
06.17.2019 | CARB-X awards Oxford Drug Design funding to develop a new class of antibiotics to treat drug-resistant Gram-negative infections
CARB-X is awarding Oxford Drug Design Ltd. of Oxford, UK, up to $2.55 million in non-dilutive funding with the possibility of $4.24 million more if certain project milestones are met, to develop a new class of antibiotics for the treatment of Gram-negative bacterial infections using an approach designed to reduce the likelihood that resistance will emerge.
-
05.14.2019 | CARB-X funds Debiopharm to develop a new class of antibiotics to treat hospital-acquired pneumonia caused by multidrug-resistant superbug Acinetobacter baumannii
CARB-X is awarding Debiopharm International SA of Lausanne, Switzerland, up to $2.1 million in non-dilutive funding with the possibility of $1.6 million more if certain project milestones are met, to advance the development of a new class of antibiotics that inhibit bacterial fatty acid biosynthesis, an essential pathway in many drug-resistant bacterial species. This new class of antibiotics is in development for the treatment of hospital-acquired pneumonia caused by the multidrug-resistant superbug Acinetobacter baumannii.
-
04.30.2019 | CARB-X launches new Funding Rounds to support the development of antibiotics, vaccines, diagnostics and other life-saving products that target drug-resistant bacteria
CARB-X announced today its 2019 rounds of funding to support the development of antibiotics, vaccines, biotherapeutics, diagnostics and other life-saving products to address the rising threat of drug-resistant bacteria. There are four funding rounds representing CARB-X’s most ambitious call for proposals from product developers seeking financial, scientific and business support to accelerate the development of innovative products targeting the most dangerous superbugs.
-
03.14.2019 | Germany joins CARB-X partnership in the fight against deadly drug-resistant superbugs
CARB-X announced today it has signed a partnership agreement with Germany’s Federal Ministry of Education and Research (BMBF) to invest €39 million over four years in the early development of antibiotics, vaccines, and diagnostics to combat drug-resistant bacteria. Under the agreement, BMBF will also provide an additional €1 million in direct support to a consortium of the German Center for Infection Research (DZIF), the Federal Institute for Vaccines and Biomedicines (PEI) and the Federal Institute for Drugs and Medical Devices (BfArM), which is joining the CARB-X Global Accelerator Network, a network of 10 accelerators around the world to support CARB-X funded projects. CARB-X is a global non-profit partnership housed at Boston University.
-
03.04.2019 | CARB-X funds ContraFect to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs
CARB-X is awarding ContraFect Corporation (Nasdaq:CFRX) of Yonkers, New York, USA, up to $1.75 million in non-dilutive funding with the possibility of $5.19 million more if certain project milestones are met, to develop novel antibiotics to treat serious life-threatening infections caused by Gram-negative ESKAPE pathogens. This is ContraFect’s second antibacterial project to earn CARB-X funding.
-
02.25.2019 | CARB-X expands its Global Accelerator Network to support the development of antibiotics, rapid diagnostics, vaccines and other life-saving products to combat drug-resistant superbugs
CARB-X is expanding its Global Accelerator Network, bringing together 10 world-class organizations from six countries (Denmark, Germany, India, Switzerland, United Kingdom, United States) into a single global network of expertise to provide scientific, technical and business support to the growing numbers of CARB-X-funded antibacterial research projects. The new accelerators join CARB-X’s existing accelerator partners – CLSI, MassBio and RTI International in the United States and the Wellcome Trust in the United Kingdom.
-
02.06.2019 | CARB-X funds Recida Therapeutics to develop a new class of antibiotics to treat deadly infections caused by Gram-negative superbugs
CARB-X is awarding Recida Therapeutics of Menlo Park, CA, USA, up to $4.4 million in non-dilutive funding to develop a novel antibiotic to treat serious infections caused by Gram-negative bacteria.
-
02.04.2019 | CARB-X funds Polyphor to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs
CARB-X is awarding Polyphor (SIX: POLN) of Allschwil, Switzerland, up to $2.6 million in non-dilutive funding with the possibility of $3.0 million more if certain project milestones are met, to develop a novel antibiotic with a novel mode of action to treat serious infections caused by Gram-negative ESKAPE pathogens.
-
01.03.2019 | CARB-X backs Forge to develop a new class of antibiotics to treat serious lung infections caused by Gram-negative bacteria, including multi-drug resistant P. aeruginosa
CARB-X is awarding Forge Therapeutics of San Diego, CA, USA, up to $5.7 million in non-dilutive funding, with the possibility of up to $5.4 million more if certain project milestones are met, to develop a novel antibiotic to treat serious lung infections caused by Gram-negative bacteria including multi-drug resistant Pseudomonas aeruginosa. This is Forge’s second project to earn CARB-X support
Toggle navigation